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1. INTRODUCTION 
1.1 CANCER 
Cancer is a group of more than 100 diseases characterized by uncontrolled 
cellular growth as a result of changes in the genetic information of cells. Cells and 
tissues are complex systems with critical stages and checkpoints to ensure normal 
growth, development, and function. Normally the division, differentiation, and death 
of cells are carefully regulated. All cancers start as a single cell that has lost control of 
its normal growth and replication processes
1
. 
 Human adults are made up of around 10
13
 cells, which are renewed and 
replaced constantly. About 5–10 per cent of cancers result directly from inheriting 
genes associated with cancer, but the majority involve alterations or damage 
accumulated over time to the genetic material within cells. The causes of damage are 
both endogenous (internal) and exogenous (environmental). Food, nutrition, and 
physical activity are important environmental factors in the development of cancer
1
. 
 Cancer is characterized by uncontrolled multiplication and spread of abnormal 
forms of the body‘s own cells2. Cancer is caused in all or almost all instances by 
mutation or by some other abnormal activation of cellular genes that control cell 
growth and cell mitosis. The abnormal genes are called oncogenes. As many as 100 
different oncogenes have been discovered
3
. It is one of the major causes of the death 
in developing nations.  The term cancer, malignant neoplasm (neoplasm means new 
growth) and malignant tumor are synonymous
2
. The study of tumors is called 
oncology. Tumors may be cancerous or fatal, or they may be harmless. A cancerous 
neoplasm is called a malignant tumor or malignancy.  
 When cells are no longer needed or become a threat to the organism, they 
undergo a suicidal programmed cell death, or apoptosis. Apoptosis is initiated by 
activation of a family of proteases called caspases. These are enzymes that are 
synthesized and stored in the cell as inactive procaspases. The mechanisms of 
activation of caspases are complex, but once activated; the enzymes cleave and 
activate other procaspases, triggering a cascade that rapidly breaks down proteins 
within the cell. The cell thus dismantles itself, and its remains are rapidly digested by 
neighbouring phagocytic cells. A tremendous amount of apoptosis occurs in tissues 
that are being re-modelled during development. Even in adult humans, billions of 
cells die each hour in tissues such as the intestine and bone marrow and are replaced 
INTRODUCTION 
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by new cells. Programmed cell death, however, is precisely balanced with the 
formation of new cells in healthy adults. Otherwise, the body‘s tissues would shrink 
or grow excessively. Recent studies suggest that abnormalities of apoptosis may play 
a key role in neurodegenerative diseases such as Alzheimer‘s disease, as well as in 
cancer and auto-immune disorders. Some drugs that have been used successfully for 
chemotherapy appear to induce apoptosis in cancer cells
3
. 
 
Figure 1: Apoptosis and Tumor 
Cancer harms the body when damaged cells divide uncontrollably to form 
lumps or masses of tissue called tumors (except in the case of leukemia where cancer 
prohibits normal blood function by abnormal cell division in the blood stream). 
Tumors can grow and interfere with the digestive, nervous, and circulatory systems 
and they can release hormones that alter body function. Tumors that stay in one spot 
and demonstrate limited growth are generally considered to be benign
4
. 
There are five broad groups that are used to classify cancer
4
.  
1. Carcinomas are characterized by cells that cover internal and external parts 
of the body such as lung, breast, and colon cancer. 
2. Sarcomas are characterized by cells that are located in bone, cartilage, fat, 
connective tissue, muscle, and other supportive tissues. 
INTRODUCTION 
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3. Lymphomas are cancers that begin in the lymph nodes and immune system 
tissues. 
4. Leukaemias are cancers that begin in the bone marrow and often 
accumulate in the bloodstream. 
5. Adenomas are cancers that arise in the thyroid, the pituitary gland, the 
adrenal gland, and other glandular tissues. 
1.2 CANCER IN INDIA 
In 2007, cancer claimed the lives of about 7.6 million people in the world
4
. 
Globally the burden of new cancer cases in 2000 was estimated to be around 10 
million with more than half of these cases originating from the developing world 
population. Although estimates vary it is estimated that by the year 2020 there will be 
almost 20 million new cases. The magnitude of the problem of cancer in the Indian 
Subcontinent in terms of sheer numbers is the most alarming. From the population 
census data for India in 1991, 609,000 new cancer cases were estimated to have been 
diagnosed in the country. This figure had increased to 806,000 by the turn of the 
century. The estimated age standardized rates per 100,000 were 96.4 for males and 
88.2 for females. The most common cancers found in males were cancers of the lung, 
pharynx, esophagus, tongue and stomach while among females cancers of the cervix, 
breast, ovary, esophagus and mouth were common Cancer
5
. 
From the beginning of 2002, 16 oncology clinical trials were granted approval 
to date. Of these two were phase I studies for chemotherapeutic agents manufactured 
by Indian Pharmaceutical companies. The studies were for non-small cell lung cancer, 
head and neck cancer and breast cancer. The year 2003 saw more clinical protocols 
being submitted for permission to conduct multinational, global studies with India as 
part of a global drug development plan. Studies that are ongoing include cancers of 
head & neck, Chronic Myelogenous Leukemia, breast, ovarian, colorectal and lung
5
.  
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Table. 1 
Type of cancer Male (%) Female (%) Total (%) 
Oral cavity 12.5 13.1 12.8 
Pharyngeal cancer 17.6 2.5 9.5 
Oesophagus 11.1 6.7 8.7 
Larynx 4.6 0.4 2.3 
Lung 6.1 1.0 3.3 
Urinary bladder 1.4 0.3 0.8 
Tobacco cancers 53.3 24.0 37.4 
India has become a destination of choice for multinational studies in the field of 
oncology due to the large patient numbers, improving regulatory processes that are 
being implemented, investigators who are research and academically inclined and the 
large number of patients. 
1.3 DIFFERENT TYPES OF CANCER
6
 
The four most common cancers are: 
 Breast Cancer  
 Colon Cancer  
 Lung Cancer  
 Prostate Cancer  
Cancers of Blood and Lymphatic Systems:  
 Hodgkin's Disease  
 Leukemia‘s  
 Lymphomas  
 Multiple Myeloma  
 Waldentrom's Disease  
Skin cancers:  
 Malignant Melanoma  
 Skin Cancer  
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Cancers of Digestive Systems:  
 Head and Neck Cancers  
 Esophageal Cancer  
 Stomach Cancer  
 Cancer of Pancreas  
 Liver Cancer  
 Colon and Rectal Cancer  
 Anal cancer  
Cancers of Urinary system:  
 Kidney Cancer  
 Bladder Cancer  
 Testis Cancer  
 Prostate Cancer  
Cancers in women:  
 Breast Cancer  
 Ovarian Cancer  
 Gynecological Cancers  
 Chorio carcinoma 
Retroperitoneal sarcomas: 
 Soft Tissue Tumors  
 Thyroid Cancer  
 Cancers of Unknown Primary Site  
There are more than 100 different types of cancer. Most cancers are named for the 
organ or type of cell in which they start. Cancers are often referred to by terms that 
contain a prefix related to the cell type in which the cancer originated and a suffix 
such as -sarcoma, -carcinoma, or just -oma. Common prefixes include
4
:  
 
INTRODUCTION 
Department Of Pharmaceutical Chemistry  6 
 Adeno- = gland 
 Chondro- = cartilage 
 Erythro- = red blood cell 
 Hemangio- = blood vessels 
 Hepato- = liver 
 Lipo- = fat 
 Lympho- = white blood cell 
 Melano- = pigment cell 
 Myelo- = bone marrow 
 Myo- = muscle 
 Osteo- = bone 
 Uro- = bladder 
 Retino- = eye 
 Neuro- = brain 
  
1.4 CAUSES OF CANCER
1
 
A number of different types of exogenous (environmental) factors are known 
causes of cancer. These include some aspects of food and nutrition that are established 
as carcinogenic by the International Agency for Research on Cancer: 
 Endogenous causes 
 Inherited germ line mutations 
 Oxidative stress 
 Inflammation 
 Hormones 
 
 Exogenous causes 
 Tobacco use 
 Infectious agents 
 Radiation 
 Industrial chemicals 
 Medication 
 Carcinogenic agents in food 
INTRODUCTION 
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1.5 PATHOGENESIS 
 It is a multifunctional disease, the biology of which is not yet fully understood. 
Cancer cells manifest, to varying degrees, four characteristics that distinguish them 
from normal cells. These are uncontrolled proliferation 
 Dedifferentiation and loss of function 
 Invasiveness 
 Metastasis 
A normal cell turns into a cancer cell because of mutations in its DNA, which 
can be acquired or inherited. A good example is breast cancer. Carcinogenesis is a 
complex multistage process. Increase in the genetic mutations will results eventually 
in cancer
2
. 
The activation of proto-oncogenes and inhibition of tumor suppressor genes 
has been implicated in the pathogenesis of cancer. Apart from this angiogenesis plays 
an important role in the pathogenesis of cancer and is a common target for most 
chemopreventive agents.  
Angiogenesis is a highly coordinated process regulated by variety of 
molecules. Vascular endothelial growth factor (VEGF) is the major regulator of tumor 
angiogenesis in lung adenocarcinoma, responsible for promoting tumor growth and 
metastasis. 
More dangerous, or malignant, tumors form when two things occur
4
:  
1. A cancerous cell manages to move throughout the body using the blood or 
lymph systems, destroying healthy tissue in a process called invasion. 
2. That cell manages to divide and grow, making new blood vessels to feed itself 
in a process called angiogenesis. 
When a tumor successfully spreads to other parts of the body and grows, 
invading and destroying other healthy tissues, it is said to have metastasized. This 
process itself is called metastasis, and the result is a serious condition that is very 
difficult to treat.  
Tumor Growth and Metastasis
7 
As a tumor grows, nutrients are provided by direct diffusion from the 
circulation. Local growth is facilitated by enzymes (e.g., proteases) that destroy 
adjacent tissues. As tumor volume increases, tumor angiogenesis factors are produced 
to promote formation of the vascular supply required for further tumor growth. 
 
INTRODUCTION 
Department Of Pharmaceutical Chemistry  8 
Almost from inception, a tumor may shed cells into the circulation. From 
animal models, it is estimated that a 1-cm tumor sheds > 1million cells/24 h into the 
venous circulation. Although most circulating tumor cells die as a result of 
intravascular trauma, an occasional cell may adhere to the vascular endothelium and 
penetrate into surrounding tissues, generating independent tumors (metastases) at 
distant sites. Metastatic tumors grow in much the same manner as primary tumors and 
may subsequently give rise to other metastases. 
Experiments suggest that through random mutation, a subset of cells in the 
primary tumor may acquire the ability to invade and migrate to distant sites, resulting 
in metastasis. 
Molecular Abnormalities
 (6&7) 
Genes and Cancer 
 Cells can experience uncontrolled growth if there are damages or mutations to 
DNA, and therefore, damage to the genes involved in cell division. Four key types of 
gene are responsible for the cell division process: oncogenes tell cells when to divide, 
tumor suppressor genes tell cells when not to divide, suicide genes control apoptosis 
and tell the cell to kill itself if something goes wrong, and DNA-repair genes instruct 
a cell to repair damaged DNA.  
 Cancer occurs when a cell's gene mutations make the cell unable to correct 
DNA damage and unable to commit suicide. Similarly, cancer is a result of mutations 
that inhibit oncogene and tumor suppressor gene function, leading to uncontrollable 
cell growth.  
Genetic mutations are responsible for the generation of cancer cells. These 
mutations alter the quantity or function of protein products that regulate cell growth 
and division and DNA repair. Two major categories of mutated genes are oncogenes 
and tumor suppressor genes. 
Oncogenes:  
These are abnormal forms of normal genes (proto-oncogenes) that regulate 
various aspects of cell growth. Mutation of these genes may result in direct and 
continuous stimulation of the pathways (e.g., intracellular signal transduction 
pathways, transcription factors, secreted growth factors) that control cellular growth 
and division, DNA repair, angiogenesis, and other physiologic processes. 
There are > 100 known oncogenes that may contribute to human neoplastic  
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transformation. For example, the ras gene encodes the Ras protein, which regulates 
cell division. Mutations may result in the inappropriate activation of the Ras protein, 
leading to uncontrolled cell growth and division. In fact, the Ras protein is abnormal 
in about 25% of human cancers. Other oncogenes have been implicated in specific 
cancers.  
These include 
 Her2/neu (breast cancer) 
 bcr-abl (chronic myelocytic leukemia, B-cell acute lymphocytic 
leukemia) 
 C-myc (Burkett's lymphoma) 
 N-myc (small cell lung cancer, neuroblastoma) 
Specific oncogenes may have important implications for diagnosis, therapy, and 
prognosis (see individual discussions under the specific cancer type). 
Oncogenes typically result from acquired somatic cell mutations secondary to 
point mutations (eg, from chemical carcinogens), gene amplification (eg, an increase 
in the number of copies of a normal gene), or translocations.  
Tumor suppressor genes:  
Genes such as the p53 gene play a role in normal cell division and DNA repair 
and are critical for detecting inappropriate growth signals in cells. If these genes, as a 
result of inherited or acquired mutations, become unable to function, genetic 
mutations in other genes can precede unchecked, leading to neoplastic transformation.  
p53, important regulatory protein, prevents replication of damaged DNA in 
normal cells and promotes cell death (apoptosis) in cells with abnormal DNA. 
Inactive or altered p53 allows cells with abnormal DNA to survive and divide. 
Mutations are passed to daughter cells, conferring a high probability of neoplastic 
transformation. The p53 gene is defective in many human cancers. As with 
oncogenes, mutation of tumor suppressor genes such as p53 or RB (retinoblastoma) in 
germ cell lines may result in vertical transmission and a higher incidence of cancer in 
offspring. 
Examples of these genes are: 
RB gene; if this genes goes bad, it can lead to the development of 
Retinoblastoma, Bone, Breast, Lung, Prostate, Bladder and other cancers. 
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p53 gene; p53 suppresser gene can arrest replication of cells with damaged 
genes until normal repair process has taken place. If cells with damaged genes grow 
and replicate, they may result in a cancer. p53 gene suppresses the growth of such 
cells. If this gene goes mutation, it can lead to the development of Breast, Colon, 
Leukemia, soft tissue sarcomas, and many other cancers. 
BRCA1; located in chromosome 17, if this genes goes bad, it can be 
associated with a very high risk of developing Breast cancer. 
BRCA2; located in chromosome 13, if this genes goes bad, it can be 
associated with a very high risk of developing Breast cancer. 
Cell Cycle in Cancer 
The cell cycle, the process by which cells progress and divide, lies at the heart 
of cancer. In normal cells, the cell cycle is controlled by a complex series of signaling 
pathways by which a cell grows, replicates its DNA and divides. This process also 
includes mechanisms to ensure errors are corrected, and if not, the cells commit 
suicide (apoptosis). In cancer, as a result of genetic mutations, this regulatory process 
malfunctions, resulting in uncontrolled cell proliferation
8
. 
The cell cycle involves a complex series of molecular and biochemical 
signalling pathways. As illustrated in the Fig. 2, the cell cycle has four phases:  
Cell cycle is an ordered series of events consisting of several sequential 
phases: G1, S, G2 and M
2
. 
 M is the phase of mitosis  
 S is the phase of DNA synthesis  
 G1 is the gap between the mitosis that gave rise to the cell and the S phase; 
during G1, the cell is preparing for DNA synthesis 
 G2 is the gap between S phase and the mitosis that will give rise to two 
daughter cells; during G2, the cell is preparing for the mitotic division into two 
daughter cells. 
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Figure.2 Normal cell cycle 
As a cell approaches the end of the G1 phase it is controlled at a vital 
checkpoint, called G1/S, where the cell determines whether or not to replicate its 
DNA. At this checkpoint the cell is checked for DNA damage to ensure that it has all 
the necessary cellular machinery to allow for successful cell division. As a result of 
this check, which involves the interactions of various proteins, a ‗‗molecular switch‘‘ 
is toggled on or off. Cells with intact DNA continue to S phase; cells with damaged 
DNA that cannot be repaired are arrested and ‗‗commit suicide‘‘ through apoptosis, or 
programmed cell death. A second such checkpoint occurs at the G2 phase following 
the synthesis of DNA in S phase but before cell division in M phase. Cells use a 
complex set of enzymes called kinases to control various steps in the cell cycle. 
Cyclin Dependent Kinases, or CDKs, are a specific enzyme family that use signals to 
switch on cell cycle mechanisms. CDKs themselves are activated by forming 
complexes with cyclins, another group of regulatory proteins only present for short 
periods in the cell cycle. When functioning properly, cell cycle regulatory proteins,  
Including CDKs and cyclins, act as the body‘s own tumor suppressors by inducing the 
death of damaged cells. Genetic mutations causing the malfunction or absence of one 
or more of the regulatory proteins at cell cycle checkpoints can result in the 
‗‗molecular switch‘‘ being turned permanently on, permitting uncontrolled 
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multiplication of the cell, leading to carcinogenesis, or tumor development
8
. p53 is a 
protein that functions to block the cell cycle if the DNA is damaged. If the damage is 
severe this protein can cause apoptosis
9
.  
 p53 levels are increased in damaged cells. This allows time to repair DNA by 
blocking the cell cycle.  
 A p53 mutation is the most frequent mutation leading to cancer. An extreme 
case of this is Li Fraumeni syndrome, where a genetic a defect in p53 leads to 
a high frequency of cancer in affected individuals.  
1.6 CANCER DRUG DISCOVERY 
Traditionally, cancer drugs were discovered through large-scale testing of 
synthetic chemicals and natural products against rapidly proliferating animal tumor 
systems, primarily murine leukemias. Most of the agents discovered in the first two 
decades of cancer chemotherapy (1950 to 1970) interacted with DNA or its 
precursors, inhibiting the synthesis of new genetic material or causing irreparable 
damage to DNA itself. In recent years, the discovery of new agents has extended from 
the more conventional natural products of which target the proliferative process, to 
entirely new fields of investigation. These new fields represent the harvest of new 
knowledge about cancer biology, leading to the discovery of drugs that inhibit novel 
molecular targets
10
.  
Similarly targeted immunological approaches use monoclonal antibodies 
against tumor-associated antigens such as her-2/neu receptor in breast cancer cells, 
often in conjunction with cytotoxic drugs. These examples emphasize that both the 
strategy for drug evaluation and the routine care of cancer patients are likely to 
undergo revolutionary changes as entirely new treatment approaches arise from new 
knowledge of cancer biology
10
. 
Cancer therapies targeted developing cell cycle-based mechanism that 
emulates the body‘s natural process in order to stop the growth of cancer cells. This 
approach can limit the damage to normal cells and the accompanying side effects 
caused by conventional chemotherapeutic agents
8
. 
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1.7 TARGETS OF CANCER RESEARCH
2
: 
Proteins 
 Nucleic acids and their precursors 
 Tublin (Micro tubular protein) 
Enzymes  
 DNA topoisomerase –I &II 
 5-α Reductase, 
 DNA polymerase 
 Ribonucleoside  diphosphate  reductase  
 Histone deacetylase (HDAC)  
 Thiomidilate  synthatase, 
 Thimydilate synthase. 
Hormones 
 Estrogens,  
 Testosterone 
 Androgen, 
 Progestin, 
Genes 
 p53, 
 EGFR 
 VEGF 
 Onco gene 
 
1.8 HISTONE DEACETYLASE (HDAC) ENZYME 
(10&11)
 
Introduction  
             The balance of histone acetylation and deacetylation is an epigenetic layer 
with a critical role in the regulation of gene expression. Histone acetylation induced 
by histone acetyltransferases (HATs) is associated with gene transcription, while 
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histone hypoacetylation induced by histone deacetylase (HDAC) activity is associated 
with gene silencing. Altered expression and mutations of genes that encode HDACs 
have been linked to tumor development 
Since them both induce the aberrant transcription of key genes regulating 
important cellular functions such as cell proliferation, cell-cycle regulation and 
apoptosis. Thus, HDACs are among the most promising therapeutic targets for cancer 
treatment, and they have inspired researchers to study and develop HDAC inhibitors. 
Biological function of (HDAC) 
HDACs are key enzymes regulating important cell processes such as cell-
cycle progression and apoptosis. Another way by which HDACs are recruited to DNA 
independently of DNA methylation involves the interaction with transcription factors 
and nuclear receptors. Focusing on the interaction with transcription factors, HDAC1 
andHDAC2 are involved in transcriptional repression regulated by the retinoblastoma 
protein Rb E2Fis a family of transcription factors involved in cell-cycle control.E2F-
containing promoters are repressed by members of the Rb family that are recruited by 
a physical interaction with the E2F protein. One possibility is that the repression of 
E2f-regulated promoters by Rb implies the recruitment of HDACs to the E2F-
containing promoters Treatment with TSA, a classical HDAC inhibitor, prevents the 
Rb-mediated repression of gene transcription  
Role of HDACs in cancer 
A typical characteristic of human cancer is the deregulation of DNA 
methylation and post translational histone modifications, in particular histone 
acetylation, which has the fatal consequence of gene transcription deregulation. The 
role of HDACs in cancer is not restricted to their contribution to histone 
deacetylation, but also to their role in deacetylation of non-histone proteins. For 
example, HDAC1interacts with the tumor suppressor p53 and deacetylates it in vivo 
and in vitro p53 is phosphorylated and acetylated under stress conditions. Since lysine 
residues acetylated in p53 overlap with those that are ubiquitinated, p53 acetylation 
serves to promote protein stability and activation, inducing checkpoints in the cell-
division cycle, permanent cell-division arrest, and cell death. 
Mutations or alterations that induce loss of function of class I HDACs may 
contribute to cancer development. The tumor-suppressor gene RB requires the 
recruitment of class I HDACs to repress gene transcription Thus, the loss of class I 
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HDAC activity could induce the expression of genes regulated by Rb, thereby 
suppressing their protective role in tumor development 
 
Figure.3 
 
A model showing a possible effect of HDAC2 mutation in cancer 
development. Class I HDACs are involved in gene transcription-repression mediated 
by retinoblastoma protein. The lost of HDAC2 function could induce the hyper 
acetylation and re expression of genes regulated by retinoblastoma protein Rb, and 
with crucial functions in cell cycle regulation. 
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Table.2 
Classification of (HDAC) enzyme
13
 
 
GROUP SIZE LOCATION 
CHROMOSOME 
CELLULAR 
DISTRIBUTION 
COMPLEX ROLE 
Class I (type Rpd3) 
HDAC 1 483 Ip34 N Sin3, NURD TC 
HDAC 2 488 6q21 N Sin3, NURD TC 
HDAC 3 423 5q31 N NCOR1/NCOR2-
GPS2-TBL1X 
TC 
HDAC8 377 Xp13 N  TC 
CLASS IV 
HDAC11 347 3p25.2 N   
CLASS II (TYPE had 1) 
HDAC4 1084 q37.2 N,C NCOR1/NCOR2 TC 
HDAC5 1122 17q21 N,C  TC 
HDAC6 1215 xp11.22 N,C   
HDAC7 855 12q13 N,C Sin3, NCOR2 TC 
HDAC9 1011 p21-p15 N,C   
HDAC10 669 22q13.31 N,C NCOR2 TC 
Size is expressed in amino acid number, N: nuclear, C: cytoplasm, TC: Transcription 
corepressor. 
 
1.9 MOLECULAR MODELLING (14) 
 Computational chemistry/molecular modeling is the science (or art) of 
representing molecular structures numerically and simulating their behavior 
with the equations of quantum and classical physics. Computational chemistry 
programs allow scientists to generate and present molecular data including 
geometries (bond lengths, bond angles and torsion angles), energies (heat of 
formation, activation energy, etc.), electronic properties (moments, charges 
and ionization potential and electron affinity), spectroscopic properties 
(vibrational modes, chemical shifts) and bulk properties (volumes, surface 
areas, diffusion, viscosity, etc.). As with all models however, the chemist's 
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intuition and training is necessary to interpret the results appropriately. 
Comparison to experimental data, where available, is also important to guide 
both laboratory and computational work. 
 Molecular Graphics: It allows the 3D visualization and manipulation of 
structure to allow visualization of different parts of molecule, to change the 
orientation of specific function while holding other constant and to look at 
other different feasible conformations. Stereochemistry relationship including 
detailed measurement of molecular geometry and conformations, calculations 
of electron densities, electrostatic potentials, energies and direct comparison of 
the key structural features of a range of biologically active structures can be 
done by molecular graphics. 
 Computational Chemistry: It is concerned with the simulation of atomic and 
molecular properties of compounds of medicinal interest through equations 
and with the numeric methods used to solve these equations on the computer.  
 Statistical Modelling: It encompasses the search for quantitative relationship 
between the structure or properties of a series of compound and their resultant 
biological activities. 
Functions of Molecular Modelling 
1. Structure Generation: Molecular structure may be generated by a variety of    
procedures:   
 The crystal structure (if available) can be loaded from Cambridge 
crystallographic      data file. 
 2D structure can be converted to 3D by software programs such as Chem 
Office 
 The structure can be built up by stitching together small fragments. 
 By modifying a known structure. 
2. Structure Visualization: One of the most popular uses of molecular 
modelling system is to visualize molecular structures in a desired form. Different 
methods are here to represent molecular structures: 
 Ball and Stick representation  
 Colored Stick representation 
 Space Fill representation 
 Stereo Line representation 
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3. Conformation Generation: The biological activity of a drug molecule is 
supposed to depend on one single, unique conformation hidden among all the low 
energy conformations. Only the bioactive conformation can bind to the specific 
macromolecular environment at the active site of the receptor protein. It is widely 
accepted that bioactive conformation is not necessarily identical with the lowest 
energy-conformation. However, on the other hand it cannot be the conformation 
that is so high in energy that it is excluded from the population of conformations 
in solution. With the help of molecular modelling various conformations of a 
molecule can be explored. There are three methods for exploring of the 
conformations of a molecule: 
 Systematic or Grid search. 
 Model building methods. 
 Random methods 
 Molecular Interaction
16
 (Docking)
 
  
The interaction of a drug with its receptor is a complex process. Many factors 
are involved in the intermolecular association such as hydrophobic; Van der Waal‘s, 
hydrogen bonding and electrostatic forces.  
The process of ―DOCKING‖ a ligand to binding sites tries to mimic the 
natural course of interaction of the ligand and its receptor via a lowest energy 
pathway. Usually the receptor is kept rigid while the conformation of the drug 
molecule is allowed to change. The molecules are physically moved closer to one 
another and the preferred docked conformation is minimized. Molecular docking is a 
study of how two or more molecular structures, for example drug and enzyme or 
receptor of protein, fit together. The most important application of docking software is 
virtual screening. In virtual screening the most interesting and promising molecules 
are selected from an existing database for further research. This places demands on 
the used computational method; it must be fast and reliable. 
Glide (Schrödinger)
 18
 
 
Glide uses a hierarchical series of filters to search for possible locations of the 
ligand in the active site region of the receptor. The shape and properties of the 
receptor are represented by a grid using several different sets of fields that provide 
progressively more accurate scoring of the ligand poses. Conformational 
flexibility is handled in Glide by an extensive conformational search, augmented by a 
heuristic screen that rapidly eliminates unsuitable conformations, such as 
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conformations that have long range internal hydrogen bonds and high energy 
conformers. Glide can also dock sets of pre-computed conformations. However, Glide 
offers its greatest value when conformations are generated internally. For each core 
conformation (or for rigid docking, each ligand), an exhaustive search of possible 
locations and orientations is performed over the active site of the protein. The search 
begins with the selection of ―site points‖ on an equally spaced 2 Å grid that covers the 
active site region. 
The second stage of the hierarchy begins by examining the placement of atoms 
that lie within a specified distance of the line drawn between the most widely 
separated atoms (the ligand diameter). This is done for a pre-specified selection of 
possible orientations of the ligand diameter (Step 2a). If there are too many steric 
clashes with the receptor, the orientation is skipped. Next (Step 2b), rotation about the 
ligand diameter is considered, and the interactions of a subset consisting of all atoms 
capable of making hydrogen bonds or ligand-metal interactions with the receptor are 
scored (subset test). If the score is good enough, all interactions with the receptor are 
scored (Step 2c). The scoring in these three tests is carried out using Schrödinger‘s 
discretized version of the ChemScore empirical scoring function. Much as for 
ChemScore itself, this algorithm recognizes favourable hydrophobic, hydrogen-
bonding, and metal-ligation interactions, and penalizes steric clashes. This stage is 
called ―greedy scoring,‖ because the actual score for each atom depends not only on 
its position relative to the receptor but also on the best possible score it could get by 
moving ±1 Å in x, y, or z. This is done to mute the sting of the large 2 Å jumps in the 
site-point/ligand-centre positions. The final step in Stage 2 is to re-score the top 
greedy scoring poses via a ―refinement‖ procedure (Step 2d), in which the ligand as a 
whole is allowed to move rigidly by ±1 Å in the Cartesian directions. 
Only a small number of the best refined poses (typically 100-400) is passed on 
to the third stage in the hierarchy—energy minimization on the pre-computed OPLS-
AA van der Waals and electrostatic grids for the receptor. The energy minimization 
typically begins on a set of van der Waals and electrostatic grids that have been 
―smoothed‖ to reduce the large energy and gradient terms that result from too-close 
interatomic contacts. It finishes on the full-scale OPLS-AA non-bonded energy 
surface (―annealing‖). This energy minimization consists only of rigid-body 
translations and rotations when external conformations are docked. When 
conformations are generated internally, however, the optimization also includes 
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torsional motion about the core and end-group rotatable bonds. Unless otherwise 
specified, a small number of the top-ranked poses are then subjected to a sampling 
procedure in which alternative local minima core and rotamer-group torsion angles 
are examined to try to improve the energy score. 
 
Figure.4 Glide docking hierarchy 
 
 Energy Calculation and Energy Minimization
 (17)
 
It was hypothesized that a ligand or drug binds to the enzyme or receptor in its 
most stable form i.e. ‗minimum energy state‘ form and hence properties of this energy 
optimized molecule will give the information regarding physicochemical 
requirements which govern the biological activities. This forms the basis of energy 
calculation and energy minimization. Energy minimizing procedures can be divided 
in to two classes: 
 First derivative techniques (e.g. Steepest Descent, Conjugate Gradient, and              
Powell method).  
 Second derivative techniques (e.g. Newton-Raphson) 
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2. LITERATURE REVIEW 
Anti-cancer 
Chetan
1
 et al (2010) had synthesised and reported piperezine hydroxymic acid 
derivatives as HDAC8 inhibitors. They screened for their anticancer activity against 
HL60 human promyelocytic leukaemia cell line due to the presence of 
pharmacophoric features Compound 1 had IC50 of 0.6l µM. 
 
 
(1) 
 
Kim
2
 et al (2006) had reported the δ-Lactam-based hydroxamic acid, inhibitors of 
histone deacetylase (HDAC). The compound (2) exhibited growth inhibitory activity 
on five human tumor cell lines, showing good sensitivity on the MDA-MB-231 breast 
tumor cell line. 
 
 
(2) 
 
Kemp
3
 et al (2011) they are investigated a small molecule with a novel hydroxy-
pyrimidine scaffold that inhibits multiple HDAC enzymes and modulates acetylation 
levels in cells. Compound (3) has found to be potent in order to evaluate structure–
activity relationships. 
 
(3) 
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Donald
4
 et al (2010) has synthesized and reported the novel HDAC series 
demonstrating inhibitory activity in cell proliferation assays is described. The 
compound (4) was good activity against human colon cancer cell line. 
  
(4) 
Bieliauskas
5
 et al (2007) had synthesised and reported a small molecule library with a 
variety of substituent’s attached adjacent to the metal binding hydroxamic acid of 
SAHA. The compound (5) has more inhibitory activities in the nanomolar range. 
 
 
(5) 
 
Paquin
6
 et al (2008) had synthesed and biological evaluated of a variety of 4-
(heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides is presented herein. The 
compound (6) showed the best HDAC1 enzyme inhibitory action and in vitro anti-
proliferative activities with IC50 values below micro molar range. 
 
 
 
(6) 
 
Angibaud
7
 et al (2009) had designed and synthesised and reported designing 5-
pyrimidyl hydroxamic acid anti-cancer agents; they have identified a new series of 
potent histone deacetylase (HDAC) inhibitors. The compound (7) exhibit enzymatic 
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HDAC inhibiting properties with IC50 values in the nanomolar range and inhibit tumor 
cell proliferation at similar levels. 
 
(7) 
 
Price
8
 et al (2007) had synthesed a series of thienyl-based hydroxamic acids that 
included ADS100380 and ADS102550 led to the identification of the 5-pyridin-2-yl-
thiophene-2-hydroxamic acid. Substitution at the 5- and 6-positions of the pyridyl ring 
of compound (8) has excellent enzyme inhibition and anti proliferative activity.  
 
 
 
 
(8) 
 
Choi
9
 et al (2011) had synthesized δ -lactam core HDAC inhibitors which showed 
potent HDAC inhibitory activities as well as cancer cell growth inhibitory activities. 
Hydrophobic and bulky cap groups increase potency of HDAC inhibition because of 
hydrophobic interaction between HDAC and inhibitors. In overall, the compound (9) 
γ -lactam based HDAC inhibitors showed more potent than δ-lactam analogue. 
 
 
 
(9) 
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Hong Su
10
 et al (2009) had reported some novel N-hydroxybenzamide-based HDAC 
inhibitors. Introducing branched hydrophobic groups at the capping group, and their 
inhibition activity against HDACs and anti-proliferation activity in four tumor cell 
lines were determined. Compound (10) was more potent in human HDAC1 and 
HDAC4 to evaluate their selectivity profile.  
 
(10) 
 
Belvedere
11
 et al (2007) had synthesised and reported the HDAC inhibitory activity of 
a vorinostat-derived series of substrate-based HDAC inhibitors (2-L-aminosuberic 
acid) from hydroxymic acid.  The (11) compound was posses the optimal activity 
compare with vorinistate. 
 
(11) 
 
Vaisburg
12
 et al (2007) has synthesised and reported the variety of compounds of N-
(2-amino-phenyl)-4-(heteroarylmethyl)-benzamides. Compound (12) was found 
activity against HDAC1 and showed in vivo activity in various human tumor 
xenograft models in mice. 
 
(12) 
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Angibaud
13
 et al (2010) have been synthesised and reported 5-pyrimidylhydroxamic 
acid anti-cancer agents, they have identified a new series of potent histone deacetylase 
(HDAC) inhibitors. The compound (13) exhibited enzymatic HDAC inhibiting 
properties with IC50 values in the nanomolar range.  
 
 
(13) 
Anandan
14
 et al (2007) had reported a series of hydroxamic acid-based histone 
deacetylase (HDAC) inhibitors characterized by a zinc chelating head group attached 
directly to a thiazole ring. Compound (14) is potently inhibiting an HDAC enzyme   
and antiproliferative activity against the breast cancer cell line MCF7. 
 
 
(14) 
 
Nishino
15
 et al (2004) had synthesised and reported cyclic tetra peptide 
retrohydroxamic acids as histone deacetylase (HDAC) inhibitors and evaluated the 
inhibitory activity. The compound (15) has more potential as anticancer drugs. 
 
 
 
(15) 
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Jones
16
 et al (2006) had synthesised and reported the L-2-amino-8-oxodecanoic acid 
(L-Aoda) derivatives and identified a small acyclic lead molecule with the unusual 
ketone zinc binding group. The compound (16) was more potent against HDAC 
enzyme. 
 
 
(16) 
 
Lavoie
17
 et al (2001) had synthesised and reported a series of sulfonamide 
hydroxamic acid derivatives. Further optimization of this series by substitution of the 
terminal aromatic ring yielded the compound (17) was showed good in vitro and in 
vivo activities. 
 
(17) 
 
Lee
18
 et al (2007) had synthesised and reported the hydroxamic acid derivatives 
bearing a 4-(3-pyridyl) phenyl group as a cap structure. A representative compound 
(18) showed more potent growth-inhibitory activity against pancreatic cancer cells 
and greater upregulation of p21WAF1/CIP1 expression than the clinically used 
HDAC inhibitor suberoylanilide hydroxamic acid. 
 
 
(18) 
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Wada
20
 et al (2003) has synthesised Keto ester and amides of thiazole as histone 
deacetylase inhibitor. Nanomolar inhibitors against the isolated enzyme and sub-
micromolar inhibitors of cellular proliferation were obtained. The keto amide (20) 
also exhibited significant anti-tumor effects in an in vivo tumor model. 
 
 
(19) 
 
Canzoneri
19
 et al (2009) had synthesised and reported the new class of histone 
deacetylase (HDAC) inhibitors derived from conjugation of a suberoylanilide 
hydroxamic acid-like aliphatic-hydroxamate pharmacophore to a nuclear localization 
signal peptide. Compound (19) showed more potent activity against HDAC6 and 
HDAC 8 when compared to SAHA. 
 
(20) 
 
Suzuki
21
 et al (2005) had designed and synthesised several suberoylanilide 
hydroxamic acid (SAHA)-based compounds the catalytic mechanism of 
HDACs.compound (21) was found to be potent as SAHA.  
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(21) 
 
Scarpelli
22
 et al (2001) had synthesised and reported the novel series of 5-
(trifluoroacetyl) thiophene-2-carboxamides as potent and selective class II HDAC 
inhibitors. The compound (22) is valid lead compound. 
 
(22) 
 
Methot
23
 et al (2008) had synthesised and reported the the initial exploration of novel 
selective HDAC1/HDAC2 inhibitors (SHI-1:2).  Structures 23 was exhibit enhanced 
intrinsic activity against HDAC1 and HDAC2.the compound (23) is more active 
against (HDAC2) enzyme. 
 
 
(23) 
 
Pabba
24
 et al (2011) had synthesised and reported the series of (HDAC) inhibitors 
with aryl ether and aryl sulfone residues at the terminus of a substituted, unsaturated 
5-carbon spacer moiety evaluated. Compound 24 is more potent HDAC inhibitors 
with activities at low nanomolar levels. 
  
(24) 
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Loudni
25
 et al (2007) had synthesised substituted 1, 4-benzodiazepine-2, 5-dione 
moieties as cyclic peptidemimic cap structures, and a hydroxamate side chain.  The 
compound (25) exhibited promising HDAC-inhibitory activities 
 
 
(25) 
 
Shinji
26
 et al (2006) had synthesised and reported a series of hydroxamic acid 
derivatives bearing a cyclic amide/imide group as a linker and/or cap structure. 
Compound (26) showed class-selective potent histone deacetylase (HDAC)-inhibitory 
activity. 
 
 
 (26) 
 
Giannini
27
 et al (2009) had synthesised the N-hydroxy-(4-oxime)-cinnamide scaffold, 
and screened against cancer cell line NB4, H460 & HCT116. Compound (27) was 
more potent against that three cancer cell lines. 
 
(27) 
LITERATURE REVIEW 
 
Department of Pharmaceutical Chemistry  31 
Chen
28
 et al (2008) had synthesised 1, 2, 3- triazole ring as a surface recognition cap 
group linking moiety in suberoylanilide hydroxamic acid-like (SAHA-like) HDAC 
inhibitors. The compound (28) is more potent against HDAC inhibition and cell 
growth inhibitory activities. 
 
 
(28) 
 
Hanessian
29
 et al (2007) explored a series of alkoxy ethers with variation of the length 
of the aliphatic chain of suberoylanilide hydroxamic acid (SAHA, vorinostat).   The 
compound (29) showed the best activity against human cancer cell line NB4, H460 & 
HCT-116. 
 
 
 
(29) 
Rossi
30
 et al (2011) had reported the N-substituted 4-alkyl piperidine hydroxamic 
acid. The compound (30) was identified as more potent against cancer cell line HCT-
116. 
 
 
(30) 
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3. METHADOLOGY 
3. 1. RESEARCH ENVISAGED 
Histone deacetylases (HDACs) are enzymes involved in many important 
biological functions. They have been linked to a variety of cancers, psychiatric 
disorders. Histone deacytylase is the important target for cancer research. HDAC has 
majorly two types. Sub type (HDAC) 8 is more efficient target for hydroxymate 
derivatives. Literatures revealed that various aryl and hetroaryl, derivatives are an 
ideal linker to design HDAC inhibition. Recently chetan
1
 et al explored piperazine as 
a linker for hydroxamic acid derivative as HDAC inhibitors with IC50 of micromolar 
range. This prompted us to synthesize a newer analogue of  piperazine isoster 
piperidine as a newer hydraxamic acid derivatives with enhanced spectrum of activity 
which  were designed by molecular modeling software, based on this the best 
molecule would be synthesized and evaluated for the Histone deacetylases (HDACs) 
inhibitory action   
 
 
                                   
             CAP         LINKER       ZBG                         CAP         LINKER       ZBG 
From above consideration we  
 Synthesis of some novel piperidine hydroxamate derivatives. 
 Characterization of synthesized compounds by various analytical techniques 
like TLC, FTIR, H
1
NMR and Mass Spectral studies. 
BIOLOGICAL SCREENING 
 Screening for in vitro anticancer activity against (HeLa) cervical cancer cell 
line by MTT assay method. 
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Scheme 1 
 
 
Reaction& condition: 
(a) CH3OH, (C2H5) N, (3hr stirring); (b) CH3OH, CH3COOH (2-3hr reflux); 
(c) Metylpiperidine-4-corboxylate, CH3OH, (6-8 hrs reflux); (d) K2CO3, (C2H5)2 O, 
NH2OH.HCl, (1-2 hrs stirring). 
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Scheme  2 
 
 
 
Reaction& condition:  
(a)CH3OH, (C2H5) N, (3hr stirring); (b) Lawesson’s reagent, toluene, (2hrs reflux);  
(c) CH3OH, CH3COOH (2-3hr reflux); (d) Metylpiperidine-4-corboxylate, CH3OH,           
(6-8   hrs reflux); (e) K2CO3, (C2H5)2 O; NH2OH.HCl, (1-2 hrs stirring). 
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Phase-2 
Characterization:  
All the newly synthesized compounds will be characterized by Melting point 
determination; Solubility property, TLC analysis and their structure will be elucidated 
by UV Spectroscopy, IR-Spectroscopy, H
1
NMR –Spectroscopy and MASS- 
Spectroscopy. 
Phase-3 
Biological evaluation: 
In vitro anticancer screening 
All synthesized compounds would subject for in vitro anticancer activity on 
the cervical cancer cell line (HeLa).. 
3.2 DOCKING ANALYSIS
8
: 
Compounds 1-53 were used for docking on 1 cancer protein histone 
deacetylase (HDAC) PDB ID: 1T69. 
Glide docking uses the assumption of a rigid receptor, although scaling of van 
der Waals radii of nonpolar atoms, which decreases penalties for close contacts, can 
be used to model a slight “give” in the receptor and/or ligand. Docking studies of 
designed compounds were carried out using GLIDE (Grid-based Ligand Docking 
with Energetics) module version 4.5, Schrödinger, LLC, New York, NY, 2007. The 
software package running on multi-processor Linux PC. GLIDE has previously been 
validated & applied successfully to predict the binding orientation of many ligands. 
 
DOCKING METHODOLOGY 
The steps involved in docking are as follows: 
 Ligand structure: The chemical structure of each ligand was drawn using build 
module. 
 Ligand preparation:  In order to prepare high quality, all-atom 3D structures for 
large numbers of drug-like molecules, starting with the 3D structures in SD 
Maestro format, LigPrep was used. LigPrep produced a single, low-energy, 3D 
structure with corrected chiralities for each successfully processed input structure. 
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 Preparation of protein: The typical structure ﬁle from the PDB is not suitable for 
immediate use in molecular modelling calculations. A typical PDB structure ﬁle 
consists only of heavy atoms and may include a co-crystallized ligand, water 
molecules, metal ions, and cofactors. Some structures are multimeric, and may 
need to be reduced to a single unit. Because of the limited resolution of X-ray 
experiments, it can be difficult to distinguish between NH and O, and the 
placement of these groups must be checked. PDB structures may be missing 
information on connectivity, which must be assigned, along with bond orders and 
formal charges. This was done using the Protein Preparation Wizard. 
 Receptor Grid Generation: Receptor grid generation requires a “prepared” 
structure: an all atom structure with appropriate bond orders and formal charges. 
Glide searches for favourable interactions between one or more ligand molecules 
and a receptor molecule, usually a protein. The shape and properties of the 
receptor are represented on a grid by several different sets of fields that provide 
progressively more accurate scoring of the ligand poses. The options in each tab of 
the Receptor Grid Generation panel allow defining the receptor structure by 
excluding any co-crystallized ligand that may be present, determine the position 
and size of the active site as it will be represented by receptor grids, and set up 
Glide constraints. A grid area was generated around the binding site of the 
receptor. 
 Ligand Docking: This is carried out using GLIDE DOCK. Glide searches for 
favourable interactions between one or more ligand molecules and a receptor 
molecule, usually a protein. Each ligand acts as single molecule, while the 
receptor may include more than one molecule, e.g., a protein and a cofactor. Glide 
was run in rigid or flexible docking modes; the latter automatically generated 
conformations for each input ligand. The combination of position and orientation 
of a ligand relative to the receptor, along with its conformation in flexible docking, 
is referred to as a ligand pose. The ligand poses that Glide generates pass through 
a series of hierarchical filters that evaluate the ligand’s interaction with the  
receptor. The initial ﬁlters test the spatial ﬁt of the ligand to the deﬁned active site, 
and examine the complementarity of ligand-receptor interactions using a grid-
based method patterned after the empirical ChemScore function. Poses that passed 
these initial screens entered the ﬁnal stage of the algorithm, which involves 
evaluation and minimization of a grid approximation to the OPLS-AA non bonded 
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ligand-receptor interaction energy. Final scoring is then carried out on the energy-
minimized poses. 
 Glide Extra-Precision Mode (XP)-The extra-precision (XP) mode of Glide 
combines a powerful sampling protocol with the use of a custom scoring function 
designed to identify ligand poses that would be expected to have unfavourable 
energies, based on well-known principles of physical chemistry. The presumption 
is that only active compounds will have available poses that avoid these penalties 
and also receive favourable scores for appropriate hydrophobic contact between 
the protein and the ligand, hydrogen-bonding interactions, and so on. The chief 
purposes of the XP method are to weed out false positives and to provide a better 
correlation between good poses and good scores. Extra-precision mode is a 
refinement tool designed for use only on good ligand poses. Finally, the 
minimized poses are re-scored using Schrödinger’s proprietary GlideScore scoring 
function. GlideScore is based on ChemScore, but includes a steric-clash term and 
adds buried polar terms devised by Schrodinger to penalize electrostatic 
mismatches: 
 
Glide Score = 0.065*vdW + 0.130*Coul + Lipo + Hbond + Metal + BuryP + 
RotB + Site  
 
 
 
 
 
 
Table: 3 Components of Glide Score of Docking (Extra-Precision Mode) 
Component Description 
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VdW Van der Waals energy is calculated with reduced net ionic charges 
on groups with formal charges, such as metals, carboxylates, and 
guanidiniums. 
Coul Coulomb energy is calculated with reduced net ionic charges on 
groups with formal charges, such as metals, carboxylates, and 
guanidiniums. 
Lipo Lipophilic contact term. Rewards favourable hydrophobic 
interactions. 
HBond Hydrogen-bonding term is separated into differently weighted 
components that depend on whether the donor and acceptor are 
neutral, one is neutral and the other is charged, or both are 
charged. 
Metal Metal-binding term used only for the interactions with anionic 
acceptor atoms is included. If the net metal charge in the apo 
protein is positive, the preference for anionic ligands is included; 
if the net charge is zero, the preference is suppressed. 
BuryP Penalty for buried polar groups. 
RotB Penalty for freezing rotatable bonds. 
Site Polar interactions in the active site. Polar but non-hydrogen-
bonding atoms in a hydrophobic region are rewarded. 
 
 
Docking Procedure: 
The computational modeling studies relied upon the GLIDE (Grid-based 
Ligand Docking from Energetics) program (Glide, version 5.0, Schrodinger, LLC 
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New York, 2008) for the docking simulations.  These simulations were performed 
using the X-ray crystal structure of the human HDAC 8 complexed with SAHA (PDB 
ID: 1T69). All the water molecules in the crystal structure were deleted, bond orders 
were assigned, hydrogen’s were added and the protein was then further refined for the 
docking studies by processing it using Schrodinger’s Protein preparation wizard.  This 
procedure minimizes the protein to 0.30 Å RMSD using OPLS-2001 force field. 
Ligands were prepared using build panel in maestro. Further the ligands were 
prepared for docking using LigPrep tool and were energy minimized using MMFF 
Force Field. Glide Grid generation panel has been used to generate receptor grid for 
docking. Default SP (Standard Precision) docking protocol was used to dock the 
library ligands.  
Molecular docking were performed for 53 compounds using the GLIDE 
program (Version 5.0, Schrodinger, LLC, New York, 2008) to understand the 
interaction of 3k with HDAC8. The Maestro user interface (version8.5, Schrodinger, 
LLC, New York, 2008) was employed to set up and execute the docking protocol and 
also for analysis of the docking results. Human HDAC8 (PDB ID: 1T69) was selected 
for docking studies and was prepared for docking through protein preparation wizard, 
energy minimization has been carried out using OPLS2001 force field. Structures of 
1a-1m were sketched using built panel on Scheme 1&2. Maestro and prepared for 
docking through Ligprep module (energy minimized using MMFF force field). 
GLIDE grid generation wizard has been used to define the docking space. Docking 
was performed using SP (Standard Precision mode) docking protocol. The molecular 
docking results are presented in Table 2. ZBG hydroxamate functional group of all 
the molecules were found to be close to Zn2+ atom in the active site, and establishes a 
hydrogen bond with TRP 137 and GLY139 which shows the major and favorable 
interaction of the ligands with HDAC8 (Fig.3l). Amongst the nine molecules docked, 
compound 3l was the one with the best Glide and E model score of (-8.30 & 92.2) 
respectively. It exhibited two hydrogen bonding interaction with TRP 137 and 
GLY139 (Fig. 3k). The hydroxamate group is placed near the Zn2+ atom.  
 
Table: 4 
MOLECULAR DOCKING 
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CODE GLIDE SCORE E MODEL SCORE 
E14 -9.6014 -89.7972 
E8 -8.3436 -92.9220 
3l -8.2066 -60.5982 
E1 -7.8502 -60.3135 
E14 -7.3526 -83.6240 
E3 -5.9720 -39.3396 
3k -5.8887 -0.5451 
E3 -4.8042 37.6200 
E7 -2.7761 -14.2221 
 
 
Snapshots of drug-receptor interaction 
 
Fig .5 Interactions of (E14) active site residues with 1T69 
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Fig .6 Interactions of (E8) active site residues with 1T69 
 
Fig.7 Interaction of (3k) active site residues with 1T69 
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Fig.8 Interaction of (E1) active site residues with 1T69 
  
 
Fig .9 Interactions of (E3) active site residues with 1T69 
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Fig .10 Interactions of (3l) active site residues with 1T69 
 
 
Fig .11 Interactions of (E7) active site residues with 1T69 
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Fig .12 Interactions of (SAHA) active site residues with 1T69 in HIS 142 
Validation of docking protocol was done by redocking. Human HDAC8 bound to 
SAHA (PDB ID: 1T69) was selected for docking studies by using autodock version 
4.0 
 Ligand constructed by tube representation 
 Hydrogen bond interaction is representated by yellow broken lines 
 Green colour representated protien human HDAC8  ID:1T69 
 Blue colour representated SAHA standard drug (HDAC) inhibitor 
 Red dotted line indicated hydrogen bond inraaction 
 
 E14 is best glide score and E model score (-9.6014 & -89.7972) respectively. 
ZBG hydroxamate functional group  of the molecule were found to Zn
2+  
atom 
in the active site, and establishes a hydrogen bond interaction with 2925 ARG 
37 and shows the major favourable interaction of ligand with HDAC. 
 E8 is one of the best glide score and E model score (8.3436 &-92.9220) 
respectively. ZBG hydroxamate functional group  of the molecule were found 
to Zn
2+ 
 atom in the active site, and establishes a no hydrogen bond interaction 
with HDAC. 
 3k is one of the best glide score and E model score (-8.2066 &-60.5982) 
respectively. ZBG hydroxamate functional group of the molecule were found  
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to Zn
2+ 
atom in the active site, and establishes a hydrogen bond interaction 
with (858 TRP137 O&GLY137) and shows the major favourable interaction 
of ligand with HDAC. 
 E1 is one of the best glide score and E model score (-7.8502&-60.3135) 
respectively. ZBG hydroxamate functional group of the molecule were found 
to Zn
2+  
atom in the active site, and establishes a no hydrogen bond interaction 
ligand with HDAC. 
 E3 is one of the best glide score and E model score (-5.9720&-39.3396) 
respectively. ZBG hydroxamate functional group of the molecule were found 
to Zn
2+ 
atom in the active site, and establishes a hydrogen bond interaction 
with  (113CYS 280&971GLY 151 O) and shows the major favourable 
interaction of ligand with HDAC. 
 3l is one of the best glide score and E model score (-5.8887&-0.5451) 
respectively. ZBG hydroxamate functional group  of the molecule were found 
to Zn
2+ 
 atom in the active site, and establishes a no hydrogen bond interaction 
with HDAC. 
 E7 is one of the best glide score and E model score (-2.7761&-14.2221) 
respectively. ZBG hydroxamate functional group of the molecule were found 
to Zn
2+  
atom in the active site, and establishes a hydrogen bond interaction 
with  (HIE 143&ARG37) and shows the major favourable interaction of 
ligand with HDAC 
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3.3 EXPERIMENTAL 
General Procedure:  
Scheme 1 
Step 1 
 General procedure for preparation of ethyl hydrazinecarboxylate:
 2
(1) 
An equimolar quantities of hydrazine hydrate (0.1mol, 0.52ml) and ethyl 
chloroformate (0.1mol, 9.4 ml) and triethyl amine (0.1mol, 14.27 ml) and were 
dissolved in methanol and stirred  for 2 hours under room temperature. A white 
precipitate was separated, filtered and dried in a vacuum to yield ethyl 
hydrazinecarboxylate 
Step 2 
General procedure for the synthesis of Schiff’s base of Ethyl 2- substituted 
methylidene hydrazine carboxylate
2
 (1a-j): 
Ethyl hydrazino formate (1.04g, 0.01mol) and substituted benzaldehydes 
(0.01mol) were dissolved in methanol and maintained the pH 4-5 using glacial acetic 
acid. It was refluxed for 1-3 hours and the reaction was monitored by thin layer 
chromatography using (methanol: chloroform) 1:1 as mobile base.  After completion, 
the reaction mixture was poured into crushed ice and precipitate was filtered and 
recrystalized from methanol, to yield a pure compound as a green crystals of Ethyl 2- 
substituted methylidene hydrazine carboxylate.  
Step 3 
General procedure for synthesis of  substituted  methyl  1-(ethylidine 
aminocarbamoyl)  piperidine -4-carboxylate
2
 (2a-j): 
An eqimolar quqntities of methyl piperidine – 4 –carboxylate (1.34ml, 
0.01mol) and Ethyl 2- substituted methylidene hydrazine carboxylate (0.01mol) were 
dissolved in methanol and refluxed for 6-8 hours. The reaction was monitored by TLC 
using (methanol: chloroform) 1:1. Then the reaction mixture was poured into crushed 
ice. The precipitate was filtered and recrystalized from methanol or chloroform to 
yield a pure compound as a green crystals of substituted  methyl  1-(ethylidine 
aminocarbamoyl)  piperidine -4-carboxylate(2a-2j). 
Step 4 
General procedure for synthesis of substituted 4-(hydroxycarbamoyl)-N'-
ethylidenepiperidine-1-carbohydrazide
1
 (3a-j): 
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Substituted 4-(hydroxycarbamoyl)-N'-ethylidenepiperidine-1-carbohydrazide 
was synthesized by using modified procedures of Grobner and Steinberg. Equimolar 
quantity of (0.06 mol) of substituted  methyl  1-(ethylidine aminocarbamoyl)  
piperidine -4-carboxylate was added to the mixture of hydroxylamine hydrochloride 
(0.06mol) and potassium carbonate (0.06mol) in moist ether. The above solution was 
allowed to cool at 10
0
C and stirred for 1-2 hrs and an excess solvent was evaporated 
at room temperature and recrystalized to yield a substituted 4-(hydroxycarbamoyl)-N'-
ethylidenepiperidine-1-carbohydrazide.  
Scheme 2 
Step 1  
General procedure for preparation of ethyl carbonochloridodithioate
1 
(II) 
Ethyl chloroformate (0.1mol, 9.4 ml) and (0.2mol, 8.08gm lawessons reagent 
are dissolved in toluene (20 ml) and refluxed for 2 hours and the reaction completion 
was monitored by thin layer chromatography using (methanol: chloroform) 1:1. 
Step 2 
General procedure for preparation of ethyl hydrazinecarbodithioate
1
 (III) 
An equimolar quantities of hydrazine hydrate (0.1mol, 0.52ml) and ethyl 
carbonochloridodithioate and triethyl amine (0.1mol, 14.27 ml) and were dissolved in 
methanol and stirred for 2 hours under room temperature. A white precipitate was 
separated, filtered and dried in a vacuum to yield ethyl carbonochloridodithioate. 
Step 3 
General procedure for synthesis of substituted Schiff’s base of ethyl 2- 
substituted methylidene hydrazine carbothioate
2
 (1k-m) 
Ethyl hydrazinecarbothioate (1.04g, 0.01mol) and substituted benzaldehyde 
(0.01mol) were dissolved in methanol and maintained the pH 4-5 using glacial acetic 
acid. It was refluxed for 1-3 hours and the reaction completion was monitored by thin 
layer chromatography using (methanol: chloroform) 1:1. After completion reaction 
was poured into crushed ice and the precipitate was filtered and recrystalized using 
methanol, to yield a pure compound as a green crystals of ethyl 2- substituted 
methylidene hydrazine carbothioate. 
Step 4 
General procedure for synthesis of substituted methyl (1-methyleneamino 
thiocarbomyl) piperidine -4-corboxylate
2
 (2k-m) 
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An eqimolar quqntities of methyl piperidine – 4 –corboxylate (1.34ml, 0.01 
mol) and ethyl 2- substituted methylidene hydrazine carbothioate were dissolved in 
methanol and refluxed for 6-8 hours. The reaction condition was monitored by thin 
layer chromatography using (methanol: chloroform) 1:1.  Immediately the reaction 
mixture was poured into crushed ice. The precipitate was filtered and recrystalized 
using methanol, or chloroform to yield a pure compound as a green crystals of 
substituted methyl (1-methyleneamino thiocarbomyl) piperidine -4-corboxylate (2k-
2l). 
Step 5 
General procedure for synthesis of substituted N-hydroxy-1-[(2- methylidene 
hydrazinyl) carbonothioyl] piperidine-4-carboxamide
1
 (3k-m) 
Substituted N-hydroxy-1-[(2- methylidene hydrazinyl) carbonothioyl] 
piperidine-4-carboxamide carbohydrazide was synthesized by using modified 
procedures of Grobner and Steinberg. Equimolar quantity of (0.06mol) substituted 
methyl (1-methyleneamino thiocarbomyl) piperidine -4-corboxylate was added to the 
mixture of hydroxylamine hydrochloride (0.06mol) and potassium carbonate 
(0.06mol) in moist ether and allowed to cool at 10
0
C. Then the whole solution was 
Stirred   for 1-2 hrs. The precipitate was filtered. 
Scheme 1 
Step 1 
 
(I) 
         Table. 5                                                 
Code M.F M .W Yield 
(%) 
Rf Colour Solubility 
1 C3H8N202 104.10 91 0.77 White Methanol 
 Step 2 
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Table. 6                         
*All compounds are freely soluble in DMSO & partially soluble in chloroform 
Code R 
M.F 
 
M .W M .P 
Yield 
(%) 
ClogP 
 
1a 
 
 
 
 
C10H10N2O2Cl 
 
226.66 
 
230-235 
 
44 
 
2.99 
1b 
 
 
C10H10N2O2Cl 
 
226.66 
 
240-250 
 
42 
 
2.99 
1c 
 
 
C10H10N2O2Cl 
 
226.66 
 
130-135 
 
33 
 
2.99 
1d 
 
 
 
 
 
C10H12N2O3 
 
208.21 
 
270-280 
 
48 
 
1.61 
1e 
 
 
C10H12N2O3 
 
208.21 
 
220-225 
 
43 
 
1.61 
1f 
 
 
 
C10H11N3O3 
 
237.21 
 
305-310 
 
46 
 
2.02 
1g 
 
 
 
C10H11N3O3 
 
237.21 
 
205-210 
 
53 
 
2.02 
1h 
 
 
 
C10H11N2O2F 
 
210.20 
 
135-140 
 
 
 
45 
 
2.42 
1i 
 
 
 
C10H14N2O3 
 
222.24 
 
185-190 
 
85 
 
2.19 
1j 
 
 
 
C11H14N2O4 
 
238.36 
 
245-250 
 
82 
 
1.46 
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Step 3 
 
 
Table. 7 
 
Code 
 
       R 
 
M.F 
 
M .W 
 
M .P 
 
Yield 
(%) 
 
ClogP 
 
2a 
 
 
 
 
 
C15 H18N3O3Cl 
 
 
323.77 
 
 
200-205 
 
 
92 
 
 
2.84 
 
2b 
 
 
C15H18N3O3Cl 
 
323.07 
 
153-156 
 
71 
 
2.84 
2c 
 
 
C1518N3O3CL 
 
323.07 
 
126-129 
 
70 
 
2.84 
2d 
 
 
 
 
C15H19N3O4 
 
305.33 
 
318-320 
 
66 
 
1.46 
2e 
 
 
C15H19N3O4 
 
 
248-253 
 
55 
 
1.46 
2f 
 
 
 
C15H18N405 
 
334.13 
 
330-335 
 
86 
 
1.87 
2g 
 
 
 
C15H18N405 
 
334.13 
 
227-231 
 
64 
 
1.87 
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Code 
 
R 
 
M.F 
 
M .W 
 
M .P 
 
Yield 
(%) 
 
ClogP 
2h 
 
 
 
 
C14H18N3O2F 
 
307.32 
 
140-143 
 
68 
 
2.27 
2i 
 
 
 
C16H21N3O4 
 
319.36 
 
176-179 
 
93 
 
2.04 
2j 
 
 
 
C16H21N3O5 
 
335.36 
 
231-233 
 
96 
 
1.31 
*All compounds are freely soluble in DMSO & partially soluble in chloroform 
General structure 
 
Table.8  
 
Code 
 
R 
 
M.F 
 
M .W 
 
M .P 
 
Yield 
(%) 
 
ClogP 
 
3a 
 
 
 
 
 
C
14
H
17
N
4
O
3
Cl 
 
324.76 
 
230 
 
51 
 
1.06 
3b 
 
 
C
14
H
17
N
4
O
3
Cl 
 
324.76 
 
205-215 
 
56 
 
1.06 
3c 
 
 
C
14
H
17
N
4
O
3
Cl 
 
324.76 
 
105 
 
43 
 
1.06 
3d 
 
 
C
14
H
18
N
4
O
4
 
 
306..32 
 
280 
 
24 
 
-0.31 
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*All compounds are dissolving in DMSO & partial soluble in chloroform 
 
Scheme 2  
Step 1 
 
(II) 
Table.9 
Step 2 
 
(III) 
 
Code 
 
R 
 
M.F 
 
M .W 
 
M .P 
 
Yield 
(%) 
 
ClogP 
3e 
 
 
C
14
H
18
N
4
O
4
 
 
306.32 
 
240 
 
32 
 
-0.31 
3f 
 
 
 
C
14
H
17
N
5
O
5
 
 
335.32 
 
340 
 
34 
 
0.09 
3g 
 
 
 
 
C
14
H
17
N
5
O
5
 
 
335.32 
 
220 
 
70 
 
0.09 
3h 
 
 
 
C
14
H
17 
FN
4
O
3
 
 
308.13 
 
126-130 
 
56 
 
0.49 
3i 
 
 
 
C
15
H
20 
N
4
O
4
 
 
320.34 
 
186-190 
 
86 
 
0.27 
3j 
 
 
 
C
15
H
20 
N
4
O
5
 
 
336.34 
 
220 
 
67 
 
0.46 
Code M.F M .W Yield 
(%) 
Rf Colour Solubility 
 
 
 
C3H5ClS2 
 
 
140.65 
 
 
86 
 
0.60 
 
colourless 
 
- 
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Table-10 
 
Step 3 
 
Table.11 
*All compounds are dissolving in DMSO & partial soluble in chloroform 
Step 4 
 
 
 
 
Code M.F M .W Yield 
(%) 
Rf Colour Solubility 
III 
 
C3H8N2S2 
 
136.23 
 
95 0.76 White Methanol 
Code R M.F M .W M .P 
Yield  
(%) 
ClogP 
 
1k 
 
 
 
C9H9S2N2Cl 
 
244.76 
 
180-190 
 
46 
 
3.39 
 
1l 
 
C10H12N2OS2 
 
224.06 
 
220-225 
 
65 
 
1.61 
1m 
 
 
C11H10N3OS2 
 
334.25 
 
300-310 
 
56 
 
3.35 
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Table.12 
Code R M.F M .W M .P Yield 
(%) 
ClogP 
 
    2k 
 
 
 
 
C15H18N3O2SCl 
 
339.84 
 
213-216 
 
43 
 
2.99 
 
2l 
 
 
 
 
C15H18N3O3S 
 
 
 
329.39 
 
356-370 
 
43 
 
1.61 
 
2m 
 
 
C16H17N4O4SBr 423.30 335-342 87 2.58 
*All compounds are dissolving in DMSO & partial soluble in chloroform 
Step 5 
 
Table.13  
Code R M.F M .W M .P Yield 
(%) 
ClogP 
3k 
 
 
C14H17N4O2Cl 
 
340.82 
 
265-
269 
 
76 
 
1.12 
3l 
 
 
C14H17ClN4O3s 
 
322.38 230 54 -0.16 
3m 
 
C15H26N5O4SBr 442.23 
220-
225 
96 1.34 
*All compounds are dissolving in DMSO & partial soluble in chloroform 
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3.3. ANALYTICAL WORK 
THE LAYER CHROMATOGRAPHY 
   Thin layer Chromatography is a method of analysis in which the stationary 
phase, a finely divided solid, is spread as a thin layer on a rigid supporting plate and 
the mobile phase, a liquid is allowed to migrate across the surface of the plate. 
Applications of TLC 
1. To establish the purity and authenticity of starting materials and reagents. 
2. To monitor the reactions, particularly in the case of new reactions. 
3. Assessment of purity of a crude reaction product. 
4. The optimum of experimental conditions to achieve the highest possible 
yield of product. 
            Provided that the experimental conditions are reproducible, the movement of 
any substance relative to the solvent front in a given chromatographic system is 
constant and characteristic of the substance. The constant is called as retardation 
factors (Rf) and is defined as 
                                         
Rf    =         Distance travelled by solute 
                         Distance traveled by the solvent front 
 
             True reproducibility in Rf value is, however, rarely achieved in practice due to 
minor changes in a number of variables such as: 
1. The particle size of different batches of adsorbent. 
2. The solvent composition and the degree of saturation of the chamber 
atmosphere with solvent vapor. 
3. Prior activation and storage conditions of the plates. 
4. The thickness of adsorbent layer, etc. 
It is therefore, not desirable to use Rf value in isolation as a criteria for 
identity. 
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TLC were performed as following procedure 
  Dimension of plates : 5×20cm 
  Stationary phase : Silica gel-G 9E-merck) 
  Mobile phase  : Chloroform: Methanol (1:1) 
  Technique  : Ascending 
  Detection Method : Iodine chamber 
Preparation of Plates  
Uniform slurry of silica get G was prepared by addition of distilled water. This 
was then poured into a spreading through and drawn across a series of glass plates of 
size 5×20cm, depositing a uniform layer of stationary phase of 0.25mm thickness. 
The plates were air dried and then activated by heating at 110 
0
C for one hour. The 
plates were stored over a dessicator until used. 
Mobile Phase 
Evaluation of various mobile phases was tried, alone or in combination for 
each compound in which Chloroform: Methanol (1:1) was found to be suited. 
Sample Application and Development 
The samples were applied as small spot at about 2cm form the base of the 
plate. For ascending development of the thin layer chromatogram, the plate was 
placed in a TLC Chamber, which was saturated with mobile phase containing the 
developing solvent to a depth of about 0.5cm. The solvent was allowed to move up 
the plate until it travelled a distance of about 15cm from the point of the sample, on a 
20cm plate. The plate was then removed from the chamber, the solvent front was 
marked by scratching the surface and the plate was allowed to be evaporated 
Detection 
After the chromatogram was developed the solute sports need to be made 
visible in order to determine their Rf values. Iodine  chamber was employed for the 
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detection of the compounds by placing the plate in iodine  chamber containing iodine 
crystals .The solutes were visible as amper colour  spots. 
Table.15 
Code Rf Code Rf Code Rf 
1a 0.74 2a 0.35 3a 0.70 
1b 0.70 2b 0.38 3b 0.62 
1c 0.64 2c 0.36 3c 0.81 
1d 0.74 2d 0.75 3d 0.68 
1e 0.60 2e 0.45 3e 0.74 
1f 0.64 2f 0.60 3f 0.67 
1g 0.36 2g 0.80 3g 0.85 
1h 0.62 2h 0.38 3h 0.76 
1i 0.40 2i 0.70 3i 0.90 
1j 0.45 2j 0.80 3j 0.82 
1k 0,70 2k 0.63 3k 0.70 
1l 0.36 2l 0.54 3l 0.66 
1m 0.55 2m 0.77 3m 0.60 
 
3.4. INFRARED SPECTRAL STUDY 
The range of electromagnetic radiation between 0.8 and 500µm is referred as 
infrared radiation. The IR spectrum is represented with percent transmittance as the 
ordinate and the wave number (cm-1) as the abscissa. The most commonly used 
region of IR spectrum in pharmaceutical chemistry is between 2.5µm (400cm-1) and 
16µm (625cm-1). Two major applications of IR spectrometry are characterization of 
Various molecules include Determination of identity of a compound by means 
of spectral comparison with that of authentic sample. 
Verification of the presence of functional groups in unknown molecules which is 
quite important in the structural elucidation of synthetic organic compounds or 
substances isolated from natural sources. 
Samples were prepared by KBr Disc method. Solid samples (0.5-1.Omg) were 
intimately mixed with powdered potassium bromide. Mixing was effected through 
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grinding in a smooth agate mortar and the mixture pressed between a punch and disc 
under the presence of 1, 00,000-15,000 psi into a transparent disk. 
 The infrared spectral study was done on JASCO FTIR 4100. 
 The spectral data are given as follows.All absorption values are expressed in 
wave numbers cm
-1  
 
Table. 16 
CODE ABSORBANCE cm-
1
 GROUPS 
 
3a 
 
3446.42 
3200.98 
3050.00 
2901.02 
1642.09 
1627.01 
 
Secondary amine -N-H stretch 
Hydroxyl-O-H stretch 
Aromatic -C-H stretch 
Methylene -C-H stretch 
Imino -C=N- stretch 
Aromatic -C=C- stretch 
 
3b 3250.03 
3050.04 
2930.01 
1690.04 
1630.10 
1627.01 
1100.02 
Secondary amine -N-H stretch 
Aromatic -C-H stretch 
Methylene -C-H stretch 
Amide -C=O stretch 
Imino -C=N- stretch 
Aromatic -C=C- stretch 
Aromatic -C-Cl stretch 
3c 3300.01 
2855.15 
1680.02 
1616.40 
1090.02 
 
Secondary amine -N-H stretch 
Methylene -C-H stretch 
Amide -C=O stretch 
Aromatic -C=C- stretch 
Aromatic -C-Cl stretch 
 
 
 
3d 3382.29 
3220.27 
3200.98 
3032.20 
2900.02 
1680.01 
1607.72 
650.01 
 
Secondary amine -N-H stretch 
Phenol  -O-H stretch 
Hydroxyl-O-H stretch 
Aromatic  -C-H stretch 
Methylene -C-H stretch 
Amide -C=O stretch 
Aromatic -C=C- stretch 
Phenol -O-H bend 
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CODE ABSORBANCE cm-
1
 GROUPS 
3e 3550.04 
3280.11 
3200.00 
3050.01 
2900.03 
1680.03 
1640.01 
1600.02 
650.26 
 
Secondary amine -N-H stretch 
Phenolic –O-H stretch 
Hydroxyl-O-H stretch 
Aromatic -C-H stretch 
Methylene -C-H stretch 
Amide -C=O stretch 
Imino -C=N stretch 
Aromatic -C=C- stretch 
Phenolic –O-H bend 
 
3f 3500.03 
3200.01 
2918.40 
1690.02 
1640.01 
1596.15 
1525.74 
Hydroxyl  -O-H stretch 
Secondary amine -N-H stretch 
Methylene -C-H stretch 
Amide -C=O stretch 
Imino -C=N stretch 
Aromatic -C=C- stretch 
Aromatic nitro -N=O stretch 
3g 3116.00 
3200.01 
2920.00 
1690.02 
1627.01 
1607.72 
1527.67  
 Hydroxyl -O-H stretch 
Secondary amine -N-H stretch 
Methylene -C-H stretch 
Amide -C=O stretch 
Imino -C=N stretch 
Aromatic -C=C- stretch 
Aromatic nitro -N=O stretch 
 3h 3200.03 
3050.01 
1680.05 
1612.54 
1230.01 
 
3500.03 
  
Secondary amine -N-H stretch 
Aromatic -C-H stretch 
Amide -C=O stretch 
Aromatic -C=C- stretch 
Mono sub. Aromatic -C-F 
Stretch 
Hydroxyl -O-H stretch 
 
METHODOLOGY 
 
Department Of Pharmaceutical Chemistry 63 
CODE ABSORBANCE cm-
1
 GROUPS 
3i 3300.01 
2925.15 
2800.01 
1700.02 
1640.02 
1602.90 
1250.88 
Secondary amine -N-H stretch 
Methyl -C-H stretch 
Methylene -C-H stretch 
Amide -C=O stretch 
Imino -C=N stretch 
Aromatic -C=C- stretch 
Asymmetric -C-O-C- stretch 
 3j 3449.50 
3234.94 
3174.86 
2958.90 
2850.01 
1680.01 
1615.44 
1256.67 
650.02 
Secondary amine -N-H stretch 
Phenol -O-H stretch 
Hydroxyl –O-H stretch 
Methyl -C-H stretch 
Methylene -C-H stretch 
Amide -C=O stretch 
Aromatic -C=C- stretch 
Asymmetric -C-O-C- stretch 
Phenol -O-H bend 
 
 
 
 
3k 3250.03 
3040.01 
2921.00 
1635.00 
1560.04 
1625.12 
1089.82 
Secondary amine -N-H stretch 
Aromatic -C-H stretch 
Methylene -C-H stretch 
Imino -C=N stretch 
Thiones -C=S stretch 
Aromatic -C=C- stretch 
Aromatic -C-Cl stretch 
3l 3250.04 
3050.04 
2910.01 
1640.40 
1740.00 
1624.01 
1572.00 
683.73 
Secondary amine -N-H stretch 
Aromatic -C-H stretch 
Methylene -C-H stretch 
Keto -C=O stretch 
Imino -C=N- stretch 
Aromatic -C=C- stretch 
Thiones -C=S stretch  
Phenol -O-H bend 
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Fig .13 IR spectrum of compound 3a 
CODE ABSORBANCE cm-
1
 GROUPS 
3m 3236.66 
3450.01 
1737.92 
1559.50 
1050.01 
 Hydroxyl  -O-H stretch 
Secondary amine -N-H stretch 
Keto -C=O stretch 
Thiones -C=S stretch 
Aromatic  -C-Br Stretch 
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Fig .14 IR spectrum of compound 3b 
 
 
 
 
Fig .15 IR spectrum of compound 3c 
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Fig .16 IR spectrum of compound 3d 
 
 
Fig .17 IR spectrum of compound 3e 
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Fig .18 IR spectrum of compound 3f 
 
 
Fig .19  IR spectrum of compound 3g 
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Fig .20 IR spectrum of compound 3h 
 
Fig .21 IR spectrum of compound 3i 
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Fig .22 IR spectrum of compound 3j 
 
Fig .24   IR spectrum of compound 3k 
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Fig .23 IR spectrum of compound 3l  
 
 
Fig .25 IR spectrum of compound 3m 
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3.5 NUCLEAR MAGNETIC RESONANCE SPECTROMETRY 
Nuclear magnetic spectrometry is an important tool for determining the 
structures of a molecule. NMR spectrum can give almost unbelievable detailed 
information about molecular structure: 
1. The number of signals: which tell us how many different kinds of protons 
there are in a molecule? 
2. The positions of the signals, which tell us something about the electronic 
environment of each kind of proton. 
3. The intensities of the signals, which tell us how many protons of each kind 
there are; and the splitting of a signal into several peaks, which tell us about 
the environment of a proton with respect to other, nearby protons. NMR 
spectral study was done on Bruker Fourier, Transform-NMR Spectrometer 
on selected compounds. 
 
3b:1-{[(2E)-2-(3-chlorobenzylidene) hydrazinyl] carbonyl}-N-hydroxypiperidine-
4-carboxamide 
 
8.7 (s, 1H,-NH-OH) 
7.3–7.7 (m, 4H, Ar-H), 
7.9-8 (s, 1H, CH) 
3.2-3.4 (s, 1H, NH) 
2.1-2.6 (m, 9H, H in piperidine) 
3c: 1-{[(2E)-2-(2-chlorobenzylidene) hydrazinyl] carbonyl}-N-
hydroxypiperidine-4-carboxamide 
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11.65 (s, 1H,-NHOH) 
8.9 (s, 1H, Ar-CH=) 
8.7-7.3 (m, 4H, ArH) 
3.31 (s, IH, CONH) 
2.1-2.6 (m, 9H, H in piperidine) 
3d: N-hydroxy-1-{[(2E)-2-(4-hydroxybenzylidene) hydrazine] carbonyl} 
piperidine-4-carboxamide 
 
10.09 (s, 1H, NHOH) 
8.54 (s, 1H, Ar-CH=) 
7.69-6.85 (m, 4H, ArH) 
3.4 (s, 1H, CONH) 
2.5-2.49 (m, 9H, H in piperidine)) 
2.08 (s, 1H, OH) 
3e: N-hydroxy-1-{[(2E)-2-(2-hydroxybenzylidene) hydrazinyl] carbonyl} 
piperidine-4-carboxamide 
 
11.11 (s, 1H, Ar OH) 
9.04 (s, 1H -NH-OH) 
7.7-6.9 (m, 4H, ArH) 
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3.30 (s, 1H, CONH) 
2.5-2.49 (m, 9H, H in piperidine) 
3g:  N-hydroxy-1-{[(2E)-2-(2-nitrobenzylidene) hydrazinyl] carbonyl} piperidine-
4-carboxamide 
 
8.96 (s, 1H, -NH-OH) 
8.3 (s, 1H, Ar-CH=) 
7.9-7.7 (m, 4H, ArH) 
3.30 (s, IH, CONH) 
2.52-2.49 (m, 9H, H in piperidine) 
2.08 (s, 1H, -OH) 
 
3h: 1-{[(2E)-2-(3-fluorobenzylidene) hydrazinyl] carbonyl}-N-
hydroxypiperidine-4-carboxamide 
 
8.72 (s, 1H,-NH-OH) 
7.74-7.36 (m, 4H, ArH)  
3.33 (s, 1H,-CONH) 
2.5-2.49 (m, m, 9H, H in piperidine) 
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Fig .26 
1
H NMR spectrum of compound 3b 
 
 
Fig.27 
1
H NMR spectrum of compound 3c 
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Fig .28 
1
H NMR spectrum of compound 3d 
 
 
Fig .29 
1
H NMR spectrum of compound 3e 
METHODOLOGY 
 
Department Of Pharmaceutical Chemistry 76 
 
Fig. 30 
1
H NMR spectrum of compound 3g 
 
Fig .31
1
H NMR spectrum of compound 3h 
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3.5. MASS SPECTROSCOPY 
In the technique of mass spectroscopy, the compound under investigation is 
bombarded with a beam of electrons which produce an ionic molecule or ionic 
fragments of the original species. The resulting assortment of charged particles is then 
separated according to their masses. The spectrum produced, known as mass spectrum 
is a record of information regarding various masses produced and their relative 
abundance. 
The mass spectra of selectively newly synthesized compounds were recorded on 
JEOL GCMATE instrument. 
Table. 16 
S.N. Compound code Molecular 
mass(m\z) 
Base peak Molecular ion 
peak 
1 3e 306.32 251.33 306.49 
2 3g 335.32 251.33 335.93 
3 3l 332.38 146.51 332.38 
 
 
Fig .32 Mass spectrum of compound 3e 
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Fig .33 Mass spectrum of compound 3g 
 
Fig .34 Mass spectrum of compound 3l 
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IN VITRO ANTI CANCER ACTIVITY 
4&7
  
The human cervical cancer cell line (HeLa) was obtained from National 
Centre for Cell Science (NCCS), Pune, and grown in Eagles Minimum Essential 
Medium containing 10% fetal bovine serum (FBS).  
For screening experiment, the cells were seeded into 96-well plates at plating 
density of 10, 000 cells/well and incubated to allow for cell attachment at 37
0
C, 5% 
CO2, 95% air and 100% relative humidity. After 24 h the cells were treated with serial 
concentrations of the samples. The samples were initially dissolved in 
dimethylsulphoxide (DMSO) and further diluted in serum free medium to produce 
five concentrations. One hundred microlitres per well of each concentration was 
added to plates to obtain final concentrations of 100, 50, 25, 12.5 and 6.25 µM. The 
final volume in each well was 200 µl and the plates were incubated at 37
0
C, 5% CO2, 
95% air and 100% relative humidity for 48h. The medium containing without samples 
were served as control. Triplicate was maintained for all concentrations. 
After 48h of incubation, 15µl of MTT (5mg/ml) in phosphate buffered saline 
(PBS) was added to each well and incubated at 37
0
C for 4h. The medium with MTT 
was then flicked off and the formed Formosan crystals were solubilized in 100µl of 
DMSO and then measured the absorbance at 570 nm using micro plate reader. The % 
cell inhibition was determined using the following formula.  
% cell Inhibition = 100- Abs (sample)/Abs (control) x100.  
Nonlinear regression graph was plotted between % Cell inhibition and Log10 
concentration and IC50 was determined using Graph Pad Prism software 
 All synthesized compounds were screened against screened (HeLa)human 
cervical cancer cell line at different concentration 
 
 
In vitro cytotoxicity against (HeLa) human cervical cancer cell line  
 
Table.17  
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Code Cell line Concentration 
(µM) 
% cell 
inhibition 
 3a HeLa 0.1 3.769401 
  1 6.430155 
  10 15.74279 
  100 24.68588 
3c HeLa 0.1 0.723327 
  1 7.323689 
  10 17.26944 
  100 58.13743 
3d HeLa 0.1 5.786618 
  1 12.65823 
  10 17.35986 
  100 36.52803 
3e HeLa 0.1 2.512934 
  1 10.42129 
  10 28.82483 
  100 33.1116 
3f HeLa 0.1 5.838877 
  1 8.57354 
  10 9.164819 
  100 22.32077 
3h HeLa 0.1 -1.33038 
  1 3.473762 
  10 7.169254 
  
100 18.62528 
3i HeLa 0.1 1.847746 
  1 5.912786 
  
10 8.056171 
  100 
 
 
 
 
 
 
24.68588 
 
 
 
 
 
 
METHODOLOGY 
 
Department Of Pharmaceutical Chemistry 81 
 
In vitro cytotoxicity (IC50 (µM)) against (HeLa) human cervical cancer cell line  
S.NO CODE IC50 (µM) 
1 3c 66.95 µM 
 
2 3k 17.84 µM 
 
3 3l 5.83 nM 
 
4 3m 2.836 µM 
 
Table .18 
 
Code Cell line Concentration 
(µM) 
% cell 
Inhibition 
3j HeLa 0.1 3.769401 
  1 6.430155 
  10 15.74279 
  100 24.68588 
3k HeLa 0.1 3.204272 
  1 10.48064 
  10 32.84379 
  100 88.251 
3l HeLa 0.01 3.627968 
  0.1 12.26913 
  1 32.38786 
  10 54.8153 
3m HeLa 0.1 6.675567 
  1 30.70761 
  10 71.49533 
  100 99.3992 
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Invitro anticancer activity of compound 3c on HeLa cell line 
 
Table .19 
 
 
 
 
 
 
 
 
 
 
 
Fig .35 % growth inhibition of compound 3c 
 
 
 
 
Conc 0.1 µM 1 µM 10 µM 100 µM Cont 
ABS 0.374 0.332 0.306 0.143 0.388 
 0.36 0.335 0.304 0.166 0.359 
 0.364 0.358 0.305 0.154 0.359 
Avg 0.366 0.341667 0.305 0.154333 0.368667 
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Invitro anticancer activity of compound 3c on HeLa cell line 
 
                          
                         0.1µM                                                1µM 
        
10 µM                                    100 µM 
 
control 
Fig.39 HeLa cell line inhibition by the compound 3c 
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 Invitro anticancer activity of compound 3k on HeLa cell line 
Conc 0.1 µM 1 µM 10 µM 100 µM Cont 
ABS 0.481 0.329 0.121 0.002 0.492 
 
0.461 0.34 0.154 0.005 0.488 
 
0.456 0.369 0.152 0.002 0.518 
Avg 0.466 0.346 0.142333 0.003 0.499333 
Table.20 
 
 
   
  
 
  
  
  
 
 
 
 
 
 
 
Fig .36 % growth inhibition of compound 3k 
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Invitro anticancer activity of compound 3k on HeLa cell line 
 
                
0.1µM                                                                           1µM 
                
10 µM                                                          100 µM 
 
Control 
Fig. 40 HeLa cell line inhibition by the compound 3k 
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Invitro anticancer activity of compound 3l on HeLa cell line 
Conc 0.1 µM 1 µM 10 µM 100 µM Cont 
ABS 
0.494 0.444 0.34 0.054 0.492 
 
0.486 0.445 0.347 0.069 0.488 
 
0.47 0.452 0.319 0.053 0.518 
Avg 
0.483333 0.447 0.335333 0.058667 0.499333 
Table.21 
 
 
 
 
 
 
 
 
 
Fig .37 % growth inhibition of compound 3l 
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Invitro anticancer activity of compound 3l on HeLa cell line            
     
                   
                0.1nM                                         1.0nM 
          
                10nM                                                             100nM 
         
                1000nM                                                       control 
 
Fig .41 HeLa cell line inhibition by the compound 3l 
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Invitro anticancer activity of compound 3m on HeLa cell line 
 
 
 
 
 
 
Table.22 
 
 
 
 
Fig .40 % growth inhibition of compound 3m 
 
 
 
 
 
Fig .38 % growth inhibition of compound 3m 
 
 
Conc 0.1 µM 1 µM 10 µM 100 
µM 
Cont 
ABS 0.481 0.329 0.121 0.002 0.492 
 
0.461 0.34 0.154 0.005 0.488 
 
0.456 0.369 0.152 0.002 0.518 
Avg 0.466 0.346 0.142333 0.003 0.499333 
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Invitro anticancer activity of compound 3m on HeLa cell line 
 
            
0.1µM                                                                  1µM 
       
10 µM                                                               100 µM 
 
Control 
Fig .42 HeLa cell line inhibition by the compound 3m 
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4. RESULTS AND DISCUSSION 
Chemistry and Synthesis 
Ethyl hydrazinecarboxylate was prepared from ethyl chloroformate based on 
previously reported procedures. Ethy chloroformate coupled with hydrazine hydrate in 
presence of triethyl amine to yield Ethyl hydrazinecarboxylate. The synthesis of Schiff 
base of ethyl 2- substituted methylidene hydrazine carboxylate (1a-j) are described in step 
2. Compound (I) have been coupled immediately with respective aldehydes in presence 
of glacial acetic acid to yield substituted ethyl 2- substituted methylidene hydrazine 
carboxylate. Then it was substitutedd with methyl piperidine -4-corboxylate to yield of 
substituted  methyl  1-(ethylidine aminocarbamoyl)  piperidine -4-carboxylate(2a-j) 
which undergoes base hydrolysis and followed by  substituted with hydroxalamine 
hydrochloride in presence of K2CO3 to yield substituted 4-(hydroxycarbamoyl)-N'-
ethylidenepiperidine-1-carbohydrazide.  
 
Ethyl carbonochloridodithioate was prepared from ethyl chloroformate  which 
undergoes thionation by using lawessons reagent to yield ethyl carbonochloridodithioate 
and it was coupled with hydrazine hydrate in presence of triethylamine to yield ethyl 
hydrazinecarbodithioate.
 
The synthesis of Schiff base of substituted ethyl 2- substituted 
methylidene hydrazine carbothioate (1k-m) is discribed in step 2. Ethyl 
hydrazinecarbodithioate have been coupled immediately with respective aldehydes & 
ketone in presence of glacial acetic acid to yield substituted Schiff’s base of ethyl 2- 
substituted methylidene hydrazine carbothioate. Then it was substitutedd with methyl 
piperidine -4-corboxylate to yield of substituted methyl (1-methyleneamino 
thiocarbomyl) piperidine -4-corboxylate (2k-m) which undergoes base hydrolysis and 
followed by  substituted  with hydroxalamine hydrochloride in presence of K2CO3 to 
yield substituted Substituted N-hydroxy-1-[(2- methylidene hydrazinyl) carbonothioyl] 
piperidine-4-carboxamide carbohydrazide(3k-m) 
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Physical properties 
Melting point 
Melting points were carried in open capillaries on Thomas However melting point 
apparatus which are uncorrected. A synthesized compounds melting point and its reactant 
melting points were recorded. A reactants and products melting point were differing from 
each others. It is clearly indicates that the formation of a new chemical entities. Melting 
points were given in table-1. 
Solubility 
Solubility properties of synthesized compounds were determined in various 
solvents and it was found that all compounds were completely soluble in DMSO, 
partially soluble in, chloroform and insoluble in water.  
Percentage of yield 
Percentage of yield of all synthesized compounds was calculated and values are 
given in the table-1. 
C Log P 
C Log P was calculated for all newly synthesized compounds and values are 
given in the table-1. 
Thin layer chromatography 
Thin layer chromatography was performed for all newly synthesized compound as 
well as the parent compounds, all synthesized compounds gave a single spot whose Rf 
values are different from their reactants. It ultimately shows that completion of reaction 
and purity. The Rf values are given in table-2. 
IR-Spectroscopy 
Infra red spectroscopy was taken for all newly synthesized compounds. Amide -
C=O stretch is absorbed in the region of 1680 cm
-1   
is clearly indicate the step 1.  
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Methylene -C-H stretch is strongly absorbed in 2900-2936 cm
-1
, it is clearly gives a 
chemical entities in step 2. Imino -C=N- stretch was absorbed in the region of 1635-1640 
cm
-1
 its shows that formation of Schiff base. Secondary amine –N-H sretch was observed 
in the region of 3200-3500cm
-1  
it clearly
 
indicating the proceeding of step 4. Thiones -
C=S stretch appeared in the region of 1559.50-1560 and other relevant peaks are also 
appeared, it further indicate the new chemical entities. 
1
H NMR Spectroscopy 
The 
1
H NMR spectra were taken for selected synthesized compounds (3b, 3c, 3d, 
3e, 3g & 3h). 8.2-11.6 δ ppm was appeared in all synthesized compounds. 7.3-7.9 δ ppm 
multiplet of 4H, Ar-H of benzene ring was appeared in all synthesized compounds. 2.1-
2.6 δ ppm multiplet of 9H, Piperidine acyclic proton was appeared in the entire spectrum. 
8.3 (s, 1H, -CH) Methyline proton was appeared in the spectrum. 3.30 (s, IH, CONH) 
amide proton was present in all synthesized compounds. It further estabilished the the 
structre of compounds.  
MASS Spectroscopy 
The mass spectral analysis of the synthesized compound 3e, 3g & 3k was 
performed, and their mass spectrum of the compound was in agreement with its 
molecular weight, molecular ion and base peaks are given in table-4.   
Biological activity  
In vitro anti tumor evaluation 
The antitumor activity of all compounds against human cervical cancer cell line 
(HeLa) was determined by MTT assay method. Cell line was incubated with different 
concentration for each compound and was used to create compound concentration 
various percentage of cell inhibition. These response parameter (IC50) was calculated for 
each cell line. The IC50 value corresponds to the compound’s concentration causing a net 
50% loss of initial cells at cell of the incubation period. Compound 3l (N-hydroxy-1-
{[(2E)-2-(2-hydroxybenzylidene) hydrazinyl] carbonothioyl} piperidine-4-carboxamide) 
was found to be more potent and it shows the IC50 value at 5.83nM. 
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5. CONCLUSION 
A new series of piperidine hydroxamate derivatives have been synthesized and 
evaluated for their potency as histone deacetylase inhibitors against human cervical 
cancer cell line (HeLa). Of those, compound 3l (N-hydroxy-1-{[(2E)-2-(2-
hydroxybenzylidene) hydrazinyl] carbonothioyl} piperidine-4-carboxamide) depicted as 
a potent compound with promising activity and shown IC50 value was found to be 
5.83nM.  
 
Further the lead compound would be evaluated against a panel of cancer cell lines 
and establish its possible mechanism through enzyme inhibition assay. 
  
  
Abstract 
 
 
Thirteen compounds were synthesized with piperidine in linker region and 
hydroxamate as Zinc Binding Group (ZBG). They were screened against (HeLa) human 
cervical cancer cell-line. Of those, compound 3l (N-hydroxy-1-{[(2E)-2-(2-
hydroxybenzylidene) hydrazinyl] carbonothioyl} piperidine-4-carboxamide) was found a lead 
compound with promising IC50 value of 5.83nM.   
Further the lead compound would be evaluated against a panel of cancer cell lines and 
establish its possible mechanism through enzyme inhibition assay. 
 
